1 Wall Street Analyst Thinks Tilray Will Soar Nearly 75%. Is It a Buy Now?

Roth Capital's William Kirk upgraded Tilray Brands to "buy" from "neutral" on April 2 and kept a $10 price target, citing 73% year-over-year growth in international cannabis sales and reduced domestic pricing pressure from overseas exports. The stock has fallen back to under $6 after briefly nearing $8 on U.S. legalization headlines, but the article argues a move to $10 may not require full federal legalization. Offseting this, Tilray's beverage unit is seeing declining revenue and gross profit, and the company remains unprofitable.

Analysis

The key second-order read-through is that TLRY is less a pure “U.S. legalization beta” trade than a relative-value beneficiary of a global supply re-route. If Canadian producers can arbitrage overseas demand, the domestic market can stay tighter without any meaningful U.S. federal change, which supports pricing discipline and improves the survivability of the better-capitalized names. That matters because this group has historically been priced as an all-or-nothing policy option; a more durable international sales channel can compress downside volatility even before any legislative catalyst.

The market is likely underappreciating that the most important variable over the next 1-2 quarters is not legalization headlines but earnings quality. TLRY can rerate only if international growth offsets pressure in beverages and narrows cash burn; otherwise, the stock remains hostage to speculative flows and headline decay. In other words, the path to $10 probably requires evidence of operating leverage, not just a better political backdrop, and that is a much higher bar than the recent rally implied.

Consensus appears to be missing that legalization-related spikes often create better short entries than longs once the regulatory fine print is digested. The move from ~$8 back under $6 suggests the market is already fading “hope premium,” while the next catalyst window is months away, not days. If the international thesis is real, the cleaner expression is to own the strongest balance sheet in the group or trade the sector on relative strength, rather than chase a single-name momentum rebound with binary policy risk.

Key Decisions for Investors

• Avoid chasing TLRY after the post-news fade; wait for the next earnings print or a reclaim of the prior breakout level before sizing long exposure. Risk/reward is poor near-term because upside needs operational confirmation while downside can resume quickly on policy disappointment.
• For more tactical exposure, buy TLRY call spreads 3-6 months out only on a pullback near support, targeting a rerate toward the prior high if international revenue keeps accelerating. This limits premium burn in a name where headline volatility can dominate fundamentals.
• Pair trade: long the most financially resilient cannabis operator / short TLRY if the group re-bids on legalization headlines. The thesis is that stronger balance sheets will capture the first durable re-rating while TLRY remains more sensitive to execution risk and cash burn.
• If holding no cannabis exposure, use TLRY as a short on policy exuberance spikes rather than a core long. The best short window is typically immediately after legalization headlines when the market prices in an outcome that may take quarters or years to monetize.